Anavex Life Sciences Corp. (NASDAQ:AVXL) Reports 31-Week Efficacy Results From ANAVEX 2-73 Phase 2a Study
Anavex Life Sciences Corp. (NASDAQ:AVXL) has revealed on Wednesday at the Alzheimer’s Association International Conference (AAIC) 2016 a 31-week efficacy report about the ongoing ANAVEX […]